We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
Read MoreHide Full Article
In the latest trading session, CRISPR Therapeutics AG (CRSP - Free Report) closed at $54.65, marking a -1.57% move from the previous day. This move lagged the S&P 500's daily gain of 0.5%. On the other hand, the Dow registered a gain of 0.64%, and the technology-centric Nasdaq increased by 0.43%.
The stock of company has risen by 0.8% in the past month, leading the Medical sector's loss of 0.63% and the S&P 500's gain of 0.18%.
Market participants will be closely following the financial results of CRISPR Therapeutics AG in its upcoming release. In that report, analysts expect CRISPR Therapeutics AG to post earnings of -$1.15 per share. This would mark a year-over-year decline of 161.36%. Our most recent consensus estimate is calling for quarterly revenue of $4 million, down 88.78% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$6.33 per share and a revenue of $8.54 million, indicating changes of -45.85% and 0%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.43% lower. CRISPR Therapeutics AG currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 87, positioning it in the top 36% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: Here's Why
In the latest trading session, CRISPR Therapeutics AG (CRSP - Free Report) closed at $54.65, marking a -1.57% move from the previous day. This move lagged the S&P 500's daily gain of 0.5%. On the other hand, the Dow registered a gain of 0.64%, and the technology-centric Nasdaq increased by 0.43%.
The stock of company has risen by 0.8% in the past month, leading the Medical sector's loss of 0.63% and the S&P 500's gain of 0.18%.
Market participants will be closely following the financial results of CRISPR Therapeutics AG in its upcoming release. In that report, analysts expect CRISPR Therapeutics AG to post earnings of -$1.15 per share. This would mark a year-over-year decline of 161.36%. Our most recent consensus estimate is calling for quarterly revenue of $4 million, down 88.78% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$6.33 per share and a revenue of $8.54 million, indicating changes of -45.85% and 0%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.43% lower. CRISPR Therapeutics AG currently has a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 87, positioning it in the top 36% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.